2Asano M,Yukita A,Suzuki H,et al.Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.Jpn J Cancer,1999,90(1):93-100.
3Witte L,Hicklin DJ,Zhu Z,et al.Monocolon antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.Cancer Metastasis Rev,1998,17(12):155-159.
4Prewett M,Huber J,Li Y,et al.Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.Cancer Res,1999,59(20):5209-5218.
5Fong TA,Shawver IK.SU5146 is a potent and slective inhibitor of vascular endothelial growth factor receptor (Fll1/KDR) that inhibits tyrosine kinase catalysis,tumor vasculization,and growth of multipe tumor types.Cancer Res,1999,59(1):99-106.
6Yano S,Herbst RS,Shinohara H,et al.Treatment for malignant pleural effusion of lung adenocarcinoma by inhibition of vscular endothelial growth factor recepter tyrosine kinase phosphorylation.Clin Cancer Res,2000,6(3):957-965.
7Herbst RS,Langer CJ.Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.Semin Oncol,2002,29(1 Suppl 4):27-36.
8Boehm T,Folkmam J,Browder T,et al.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.Nature,1997,390(6658):404-407.
9Gatzemeier U,Rodriguez G,Treat J,et al.Triapazamine-cisplatin: the synergy.Br J Cancer,1998,77(Suppl 4):415-417.
10Macaulay VM,O′Byrne KJ,Saumders MP,et al.Phase I study of intropleural batimastat(BB-94),a matrix metalloproteinase inhibitor,in the treatment of malignant pleural effeusions.Clin Cancer Res,1999,5(3):513-520.
